Revenue
2023
2024
2025
2026
Syncona Limited (SYNC)
Price£1.13Cached quote
Net income
2021
2022
2023
2024
2025
2026
Free cash flow
No reported data
Total cash / debt
CashTotal debt
2021
2022
2023
2024
2025
2026
Financial statements
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue | £55.9M | −£68.3M | £63.7M | −£24.0M | — | — |
| Operating expenses | £64.7M | £74.8M | £60.0M | £32.0M | — | — |
| Net income | −£8.8M | −£143.2M | £3.8M | −£56.0M | £8.8M | £53.2M |
| Net profit margin | −15.75% | — | 5.94% | — | — | — |
| Basic EPSper basic share | -£0.01 | -£0.22 | £0.01 | -£0.08 | £0.01 | £0.08 |
| Diluted EPSper diluted share | -£0.01 | -£0.22 | £0.01 | -£0.08 | £0.01 | £0.08 |
Owners
Reported major voting-rights holders
5.54%of voting rights
Saba Capital Management, L.P.Notified Sep 22, 2026
View holders
| Holder | Voting rights |
|---|---|
Saba Capital Management, L.P. | 5.54%Sep 22, 2026 · 33.67M votes |
Schroders Plc | 5.00%Mar 13, 2026 · 30.4M votes |
Jefferies Financial Group Inc | 0.15%Sep 16, 2026 · 900.82K votes |
These are threshold-crossing notices, not a complete ownership register. Percentages show issuer voting rights held through the listed share class, exclude financial instruments, and come from different dates. Positions may overlap.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: FCA National Storage Mechanism ↗Updated Sep 27, 2026
Community posts
Syncona’s Beacon investment reports positive pivotal vision-study results
Syncona ($SYNC)’s portfolio company Beacon Therapeutics reported positive topline results from its Phase II/III VISTA trial of laru-zova for X-linked retinitis pigmentosa. At 12 months, 31% of patients in the high-dose group and 24.1% in th ...
